Kamau Therapeutics shares early data on nula-cel 2.0 for sickle cell disease; 3 patients show no pain crises or transfusion ...
Sanofi drops SAR448272, a STAT6 degrader developed with Nurix Therapeutics, after Phase 1 discontinuation. Nurix shares fell ...
Biotech pessimism about China more than doubles in Q3 BPSI, making it biopharma’s No. 2 worry, while Big Pharma stays net ...
J&J’s trispecific ramantamig shows 100% ORR in newly diagnosed myeloma, Tibsovo hits EFS in frontline AML, Calquence combo ...
CVS Health (Aetna, Caremark, Oak Street) and CVS Pharmacy. CEO David Joyner leads health unit; Prem Shah leads pharmacy.
Spyre drops SPY072 for rheumatic diseases after SKYWAY trial failures; Ideaya halts darovasertib UM trial; United ...
Novo raises 2026 outlook to flat sales as the Wegovy pill outsells Lilly’s Foundayo; CFO Knudsen hands over to Galderma’s ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
Minghui Pharmaceutical will get $110 million upfront and up to $330 million in additional biobucks from Tokyo's ASKA ...
Pfizer CEO Albert Bourla says Trump’s MFN pricing deals will hold through the end of the term, even if Democrats win Congress.
Novartis ends 15-month, $802M BioArctic deal; Aulis Capital raises $200M fund; NSV closes $55M fund; Teva halts emrusolmin ...
Pfizer raises 2026 revenue guidance by $1.5B at midpoint as cancer and migraine sales offset Covid declines and it trims two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results